MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference.

Although no significant differences were observed in the root mean square deviation of each trajectory as of 100 ns, However, a highly significant rise in RMSD was observed for the CHEMBL2058939-bound 3CLpro trajectory after 100 ns of simulation time, and another sharp rise in the RMSD was observed at about 230 ns of simulation time to hit a peak of about 0.9 nm.

also in 132,142 other papers